EXCLUSIVE Jayda went to hospital with pain in her pelvis. Now doctors have diagnosed the young mum with a rare cancer with less than 200 cases - and given her less than a year to live

Jayda Chamberlain went to hospital with a simple pain in her pelvis.
The Sydney mum never imagined that she would be diagnosed with terminal cancer. Doctors performed a scan on the 22-year-old in March and noticed a large mass.
'They suspected ovarian cancer and when they went in, they discovered more masses, and sent them off for biopsy,' Ms Chamberlain's aunt, Maia Regner, told Daily Mail Australia on Friday.
'Within a week they had an answer and it wasn't an answer that we wanted.'
Ms Chamberlain was diagnosed with Desmoplastic Small Round Cell Sarcoma, an extremely rare and aggressive form of cancer.
Only about 200 cases of the variant have been reported since 1989.
Without surgery, doctors said the young mum had less than a year to live - with it, they estimated two to five years.
Ms Regner said it was a shock to hear that her niece had sarcoma because her brother, Jayda's uncle, had died from the same disease just over two years ago.
'Supposedly it's just bad luck,' Ms Regner said of the new diagnosis.
'We weren't remotely thinking sarcoma because we lost our brother to the same thing and we thought, what are the odds?
'We don't want to lose someone else. We really hate cancer - it's taken so much from our family already.'
Ms Chamberlain's abdomen is full of tumors. One nurse described them as though 'someone had thrown scattered sand'.
Doctors believe the stage four cancer had developed quickly, within the last nine months, as hospital staff would have noticed it while Ms Chamberlain was pregnant.
Ms Chamberlain first had to undergo chemotherapy with the aim of shrinking the tumors to allow for surgery. But the chemo proved too aggressive.
'She's been married for just over a year and she's got a nine-month-old baby. She doesn't want to die, she wants to fight, but the chemo has absolutely destroyed her, and she's not well enough to continue chemo,' Ms Regner said.
'We're basically clutching at straws, we're desperate to save her.'
The family has launched a GoFundMe with the aim of raising $120,000 to pay for Ms Chamberlain to undergo alternative treatments overseas in Mexico or Thailand.
The young mum has stopped chemo and is living in Sydney with her baby, Mack, and her husband Caleb.
Doctors have now deemed it too dangerous to remove her tumours through surgery.
'She just wants to be with her baby, so her thing was I want to spend as much time with my son as I can,' Ms Regner said.
'She's 22 - she shouldn't even have to be thinking about things like dying.'
On Friday, the family had raised almost $43,000 towards their goal of $120,000.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mail​

44 minutes ago

• Daily Mail​

Revealed: The most eye-wateringly pricey drugs that the NHS is paying some £3million a dose for...while dementia and cancer patients are denied cheaper treatments

NHS bosses are paying millions of pounds for just a single dose of medication to treat some of the most devastating health conditions in the world. The drugs—some of which cost just shy of £3million per patient—can revolutionise and even save the lives of a handful of people born with rare illnesses each year. But it comes as Government officials have deemed cheaper treatments for far more common conditions like dementia and breast cancer as not worth the money. Libmeldy is widely cited as the most expensive drug available on the NHS, coming in at an eye-watering £2.875million per dose. It's used to treat babies with a fatal genetic disease called metachromatic leukodystrophy (MLD). While born seemingly perfectly healthy, children with MLD have a faulty gene that leads to a destructive build-up of fat around their nerves. Over time, this severely damages their brain and nervous system, with parents forced to watch helplessly as their child gradually stops walking, talking and then eating. Roughly four babies are born with MLD every year in the UK, and have a life expectancy of just five to eight years. But Libmeldy, a one-off treatment administered as an IV drip in hospital, uses a specially designed harmless virus to alter a patients' cells and remove the faulty gene that drives MLD. It's a bespoke treatment that uses a patient's individual cells, meaning a dose is unique to each individual. Another treatment that works in a similar way is Hemgenix, which MailOnline revealed was administered for the first time by the NHS earlier week. The drug —which costs an estimated £2.6million per patient—is also a gene therapy, delivered as one-off IV drip. It is the only treatment of its kind for haemophilia B, a bleeding disorder where the body doesn't make enough—or any—of a vital protein critical to clotting. Clotting stops wounds from bleeding, so those with the disorder risk suffering severe and even life-threatening blood loss from even minor injuries. Patients also run the risk of what are called 'spontaneous bleeds', which can be triggered without a direct injury and even prove deadly if they occur in a vital organ. Prior to Hemgenix, all haemophilia B patients needed regular weekly injections of an artificial clotting agent to keep their risk of catastrophic injury to a minimum. This meant many patients were effectively tethered to their scheduled injections, unable to live their lives without worry and anxiety about every potential nick and scrape. Similar to Libmeldy, Hemgenix works by replacing a patient's defective gene—which is incapable of producing the clotting protein—with one that can, eliminating the need for regular injections. Studies suggest the protective effect lasts for at least three years, but the hope is that it could work for even longer. There are approximately 2,000 people with haemophilia B in the UK. Yet, only around 260 with 'moderately severe or severe haemophilia B' are currently eligible for Hemgenix on the NHS. This puts the potential total bill to the taxpayer at roughly £676million. While a cost of £2.6million per patient may seem prohibitive, medics claim the treating patients this way actually saves the NHS money in the long term. The lifetime cost of providing a patient the alternative weekly clotting injections has been estimated to be £8million. This sum doesn't include the cost of life-saving interventions and surgeries haemophilia B patients may also need. Another multi-million drug approved for use on the NHS is Zolgensma, which comes in at £1.8million per dose. It's designed to help babies with spinal muscular atrophy (SMA), a genetic disease that typically kills within two years if left untreated. Around 56 babies are born with SMA each year, with the condition caused by a defective gene that plays a critical role in allowing nerves in the spinal cord to control muscles movement. SMA causes muscles to waste and gets worse over time, making it difficult for patients to breathe, move and eat. Nine in 10 of those who have the most severe form of the disease, known as type 1, die by the age of two if they do not receive treatment. Zolgensma is given as one off infusion—that like the previously discussed gene therapies—also fixes the faulty gene that drives SMA. Gene therapies are incredibly expensive medications due to the intense design and manufacturing process that goes into their creation. Additionally, because many of them benefit rare health conditions with small patient populations there is an argument that companies need to charge high prices to recoup costs given the drug may only be used a handful of times per year. But exactly how much the NHS pays for these drugs isn't clear. While the companies which make the drugs do charge millions for them, the health service often acquires the medications at an undisclosed discount, so the actual cost is likely to be less than it first appears. Which drugs get funded on the NHS in England and Wales is determined by the NHS spending watchdog, The National Institute for Health and Care Excellence (NICE). In making its decisions, NICE considers a multitude of factors. These include a drug's clinical impact—how much it improves or alleviates a patient's condition—as well as risk of side effects, practical issues like specialist storage, if there are alternatives, and, critically, how much it costs. It then judges if funding the drug will overall provides value for taxpayer money. This is often summarised using a metric called a quality-adjusted life year (QALY), essentially how much it costs to give a patient a healthy year of life. Lecanemab (pictured) and donanemab are currently only available to Brits who can afford to pay around £60,000 privately every year at select clinics Generally, if a drug costs about £20,000 to £30,000 per QALY NICE usually assesses it as a good use of taxpayer funding. This isn't a hard limit. The watchdog can rule drugs that are expensive and only work for a limited time, like end-of-life medications as worth the cost, recognising small amounts of time can be worth a lot to patients and their families. However, this process isn't an an exact science and can attract controversy. For example, the breast cancer drug Enhertu, described as a lifeline by campaigners, has been deemed too expensive by NICE for what it does. However, Scotland's equivalent of NICE—the Scottish Medicines Consortium—has deemed the £10,000 per patient per month drug as value for money. Research suggests Enhertu extends the lives of patients with one of the hardest to treat forms of breast cancer, buying them an extra year or more of life. Given as an infusion, it helps patients with an aggressive and fast-growing type of the cancer called HER2-positive. NICE previously accused the firm behind the drug, AstraZeneca, of refusing to 'offer a fair price'. About 57,000 cases of breast cancer are diagnosed in the UK each year with HER2-positive cancers accounting for roughly one in five of these, some 11,500. Other drugs that have attracted controversy after being rejected by NICE are donanemab and lecanemab. Both medications are designed slow down the early stages of Alzheimer's disease, the leading cause of dementia. The drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's, helping to clear out the substance and slowing cognitive decline. However—in its most recent ruling—NICE said while the treatments worked they only delayed the progression from mild to moderate Alzheimer's by four to six months. As such, the body ruled the medications cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal the ruling. Alzheimer's is the most common cause of dementia in the UK with 944,000 Britons estimated to be living with the memory robbing disorder. NHS England published a briefing paper last year suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. While multi-million purchases of single dose drugs using taxpayer funds—as people with far more common condition are denied cheaper medications—may raise eyebrows, the cost is worth putting into context. The NHS purchasing a one off dose of a £2.875million to save a child who would otherwise die, costs roughly 4p per person in the UK. This sum is about half of £5million the NHS in England spends on dishing out the over-the-counter painkiller paracetamol every month, despite the health service banning GPs from prescribing such cheap drugs to patients in 2018.

Daily Mail​

an hour ago

• Daily Mail​

What your TONGUE says about you, according to science

It's the muscle we use every day for speaking, swallowing and tasting. But our tongue could also be an important indicator of our health and provide clues about what's going on within our body, experts say. Different colours, textures, coatings and shapes of the tongue can indicate different conditions. And keeping track of the muscular organ could help us detect issues we may otherwise be oblivious to. 'A healthy tongue is pink in colour with a slightly rough surface,' Sarah Ramage, clinical director at Bupa, said. 'What gives it this texture are the tiny bumps on top, called papillae.' Any shift from this may signal an issue or a sign that you need to work on your oral health. So, have you noticed any of these changes? RED OR WHITE PATCHES Abnormal looking patches, lumps or spots could be a sign of mouth cancer, Ms Ramage warned. Red patches could signal a condition called erythroplakia and white or grey patches may be leukoplakia, which could lead to cancer if untreated. Your dentist will look out for these when you go for a check-up, she said, and refer you to a GP or specialist if they have any concerns. 'Mouth cancer rates have increased by almost 60 per cent in the last decade, so it's important to be aware of any changes,' she added. WHITE SPOTS (LESIONS) Creamy white spots or lesions on the tongue could indicate a fungal infection, such as oral thrush. While it's usually harmless it may spread to other parts of your mouth if left untreated, causing an unpleasant taste or pain or difficulty eating and drinking. Dr Leslie Anthony is a dentist who runs her own practice in Montana. 'A red tongue may indicate heat in the body like a fever or a hormonal imbalance,' she said. 'A reddish purple tongue is a sign that there may be inflammation or an infection in the body. 'Meanwhile a pale pink tongue may be a sign of a vitamin deficiency, a weak immune system or a lack of energy.' COATING A thick coating reflects poor intestinal health or digestive issues, Dr Anthony explained. A yellowish coating indicates there may be an infection in the body, while a grey or blackish coating suggests a long-term digestive disorder or that 'something may be very wrong with your body's health'. And a thick white coating means there may be poor circulation to the extremities or possibly a yeast infection. SHAPE 'If the tongue is puffy with scalloped edges or indented teeth marks it may indicate malabsorption of nutrients,' she added. Meanwhile, a very thin tongue may be a sign of dehydration. A BLOTCHY 'GEOGRAPHIC' TONGUE A map-like pattern on the tongue's surface – with normal patches and smooth red patches – occurs when the 'old' surface of the tongue replaces itself and the top layer doesn't come off properly. It can leave a red, sore area like a scratch, but is normally harmless. The experts said it is good practice to look at young tongue in the mirror and notice the colours, textures, bumps and coating. It is best to inspect your tongue before brushing your teeth, they added. HOW TO CLEAN YOUR TONGUE Experts recommend brushing your tongue regularly to help prevent a build-up of bacteria. Tongue brushing is simple enough to do using the bristles of your toothbrush. 'The tongue harbours bacteria and food debris trapped under a thin layer of mucus,' Colgate's website reads. 'Remove this odour-causing build-up by using a small dab of toothpaste and carefully brushing the top of the tongue. 'Start by reaching to the back of the tongue, and then work forwards towards the opening of the mouth. Brush the entire top surface of the tongue using gentle pressure, and then rinse your mouth with mouthwash or water.' For those wanting a more thorough cleaning, a tongue scraper gently peels the thin mucus-based layer of debris from the tongue. WHAT IS MOUTH CANCER? Mouth cancer, also known as oral cancer, is where a tumour develops in the lining of the mouth. It may be on the surface of the tongue, the insides of the cheeks, the roof of the mouth (palate), or the lips or gums. Tumours can also develop in the glands that produce saliva, the tonsils at the back of the mouth, and the part of the throat connecting your mouth to your windpipe (pharynx). However, these are less common. Symptoms of mouth cancer include: sore mouth ulcers that don't heal within several weeks unexplained, persistent lumps in the mouth that don't go away unexplained, persistent lumps in the neck that don't go away unexplained looseness of teeth, or sockets that don't heal after extractions unexplained, persistent numbness or an odd feeling on the lip or tongue sometimes, white or red patches on the lining of the mouth or tongue – these can be early signs of cancer, so they should also be investigated changes in speech, such as a lisp See your GP or dentist if these symptoms don't heal within three weeks, particularly if you drink or smoke heavily.

Daily Mail​

4 hours ago

• Daily Mail​

EXCLUSIVE 'Miracle' side effect of common cosmetic procedure could help millions of Australians - but it'll set you back thousands

More Aussies are splashing the cash for Botox, but the trend isn't just for facial slimming, it's also helping sufferers of a painful medical condition. Nearly five million Australians experience migraines with 7.6 per cent of patients struggling with the debilitating effects more than 15 days a month, a study by Headaches Australia found. Yet despite costing the economy an estimated $35.7billion per year, patients using a procedure proven to reduce the frequency and severity of migraines need to pay out of pocket. Kate Sowden, a nurse and co-founder of Brisbane's BeautyFULL Cosmetic Medical Clinic, has noticed an increase in customers requesting jaw Botox, also known as Masseter Botox, for migraine relief. While she cannot treat migraines, she has noticed that customers who have Botox in their jaw suffer less headaches. 'I first heard about Masseter Botox being associated with migraine relief a few years ago, through both clinical discussions and feedback from patients who noticed their headaches had eased following treatment,' Ms Sowden told Daily Mail Australia. 'Masseter Botox is primarily used to help with jaw tension, teeth grinding and facial slimming, with reports of reduced headache frequency coming as a welcomed side effect.' While Botox is making waves for its medicinal applications, it is still often dismissed as only a cosmetic tool by doctors. 'Awareness has definitely grown in the past 12 to 18 months. Social media, TikTok especially, has played a big role in bringing treatments like Masseter Botox into mainstream conversations,' Ms Sowden said. 'It has helped to move away from the use for aesthetic reasons, to the use for functional benefits. 'Still, many people are surprised to learn that this kind of injectable can potentially help with tension-related symptoms.' Jude Kingston began using Masseter Botox four years ago after suffering an average of one migraine a week. 'Now I get maybe one every six weeks and, for me, the Botox normally lasts about four months,' she told Daily Mail Australia. Despite the success seen in Ms Kingston and several other Masseter Botox patients, the muscle relaxing treatment is not subsidised unless patients see a specialist. 'Cosmetic Botox, including Masseter treatment for jaw tension or aesthetic concerns, is not covered by Medicare or private health insurance in Australia,' Ms Sowden said. 'Only neurologist-administered therapeutic Botox for chronic migraines, offered under specific criteria, may qualify for a Medicare subsidy. 'It's essential that clients seeking medical migraine treatment go through the proper diagnostic channels with a neurologist.' While it's important for patients to ensure they're suited to the treatment, seeing a specialist and meeting the current subsidy criteria is a long and costly process. In order to qualify, patients must have suffered more than 15 days of headache in a month, tried at least three migraine treatments, be managed for medication overuse headache, treated by a neurologist and over 18 years old. Even if they pass eligibility, the Botox must be prescribed and administered by a neurologist. Pricing at Ms Sowden's clinic starts at $400 per session but 'varies based on muscle strength and how many units are required'. The effects of the treatment last between three and five months. 'We've definitely noticed more people enquiring about Masseter Botox in the context of migraines over the past year,' Ms Sowden said. 'Many are either undiagnosed or struggling to find long-term solutions, and come across muscle relaxant options online. 'In a cosmetic clinic like ours, we don't treat migraines medically but we can offer Masseter Botox for clients dealing with jaw clenching, TMJ discomfort, or bruxism.